IDEXX Laboratories reported second quarter 2026 revenue of $1,217 million, a 10% increase as reported and 9% organic, driven by growth in Companion Animal Group, Water, and Livestock, Poultry and Dairy segments. Diluted earnings per share reached $4.27, up 18% as reported and 15% on a comparable basis. The company raised its full-year 2026 revenue guidance to $4,700 million - $4,745 million and increased the EPS outlook to $14.69 - $14.94. IDEXX Laboratories operates in the veterinary diagnostics and pet healthcare industry.

IDEXX Laboratories shareholders approved amendments to declassify the Board of Directors over a three-year period and granted shareholders with at least 25% ownership the right to call special meetings. A separate shareholder proposal to grant special meeting rights failed, receiving 28,179,566 votes in favor and 40,019,951 against.

IDEXX Laboratories, Inc. announced its financial results for the first quarter ended March 31, 2026. The company issued a press release on May 5, 2026, detailing its results of operations and financial condition.

IDEXX Laboratories announced that Nimrata Hunt, PhD, Executive Vice President, Global Strategy and Commercial, will depart the company on April 13, 2026, due to the elimination of her position. The company will provide Dr. Hunt with separation benefits including $1,230,000 in salary continuation, $984,000 in target annual bonuses, and $50,000 for COBRA premium costs.

IDEXX Laboratories announced its financial results for the fourth quarter and full year ended December 31, 2025. The specific financial details and performance metrics are contained in the company's accompanying press release.